Clinical trial
Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and…
NCT00346099 · NSABP Foundation Inc, Other · Withdrawn
Key facts
| NCT number | NCT00346099 |
|---|---|
| Title | Study of Panitumumab Given First With Capecitabine and Oxaliplatin (CAPOX) and Then With Capecitabine and Radiation of the Pelvis for Treatment of Patients With Rectal Cancers That May or May Not Have Spread Beyond the Rectum |
| Official title | A Phase II Study to Determine the Efficacy and Safety of Panitumumab in Combination With Chemoradiotherapy for Unresectable or Locally Recurrent Adenocarcinoma of the Rectum With or Without Metastatic Disease |
| Lead sponsor | NSABP Foundation Inc, Other |
| Collaborators | Amgen Industry |
| Status | Withdrawn |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Rectal Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by, Panitumumab with capecitabine and radiation |
| Enrollment | 0 |
| Start date | Jun 1, 2006 |
| Completion | May 1, 2007 |
| First posted | Jun 29, 2006 |
| Last update posted | Jan 7, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: